TargetBeta
KLK2
kallikrein related peptidase 2 · Kallikreins
2 programs in company-led studies act on KLK2, from 1 company: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule; the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| pasritamig | Johnson & Johnson | phase 3 | 55 running | CD3E | a judged reading |
| JNJ-98768111 | Johnson & Johnson | phase 1 | 11 running | – | a judged reading |
Also acted on by the same programs
Conditions their studies are in
- Prostatic Neoplasms, 2 programs
- Prostatic Neoplasms, Castration-Resistant, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 31, 2027pasritamig · Johnson & Johnson · phase 3 · NCT04898634
- Mar 16, 2029JNJ-98768111 · Johnson & Johnson · phase 1 · NCT07746713
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.